At Epizyme, we have a comprehensive and innovative clinical development plan for tazemetostat, which we believe will have a steady stream of data over the course of the next several years. Our aim is to characterize the potential benefit of tazemetostat to patients in early lines of treatment for epithelioid sarcoma (ES) and follicular lymphoma (FL) by exploring various combination with standard of care therapies. We also plan to explore tazemetostat as both monotherapy and in combination in potential new indications.
For additional information regarding access to Epizyme’s clinical trials, please visit www.clinicaltrials.gov. You can also email us at firstname.lastname@example.org or call us at 855-500-1011 (U.S. toll-free).